Oncology

New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer

December 15, 2007
Jose Baselga
Jose Baselga

JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and so Derek Thorne got the details from Jose Baselga of Vall d’Hebron Hospital in Barcelona.

ASCO Logo New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer

Download this interview

Add podcast to iTunes

Similar Interviews

  • Audio Journal of Oncology Volume 16 Number 9

    • Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute,

  • Audio Journal of Oncology 14.1, February 2006

    • Reporting from: San Antonio Breast Cancer Symposium 2005 Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Gordon McVie, European Institute of Oncology, Milan Pat Price,

  • Audio Journal of Oncology 12.7, September 2004

    • Reporting from: - 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004 - New England Journal

    Post a comment